News, literature and expert perspectives on PCSK9 inhibition
PCSK9 Expert Opinions Prof. Wolfgang Koenig describes the results of FOURIER and SPIRE. PCSK9 inhibitors will be drugs of great value in the future, especially for patients with FH and statin intolerance.
PCSK9 Expert Opinions Prof. Richard Hobbs states that recent data from FOURIER show that effective medical treatment to lower LDL-c reduces endpoints that are important and expensive both for individuals and for health systems.
RG7652, a PCSK9 antibody, dose-dependently reduced LDL-c, ApoB and Lp(a), but not inflammatory proteins, without concerning adverse events.
PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.
PCSK9 Expert Opinions By combining all recent insights on treatment with PCSK9 inhibitors, prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.
PCSK9 Expert Opinions Dr. Paul M. Ridker states that from FOURIER and SPIRE it becomes clear that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.
PCSK9 Expert Opinions Prof. Kausik Ray describes the practical implications of the PCSK9 outcome trials. In terms of efficacy, there is no J-shaped curve, meaning there is no apparent diminution of benefit to very low LDL
PCSK9 Expert Opinions Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy. He puts the data into perspective of other trials and molecules.
PCSK9 antibody evolocumab consistently lowered LDL-C levels for an average of 44 months in a diverse patient population with hypercholesterolemia, and was well tolerated.
PCSK9 Expert Opinions Prof. John Kastelein explains the most important points from FOURIER and SPIRE 1&2. He argues that there can no longer be any doubt that lowering LDL is crucial for CVD prevention.
PCSK9 Expert Opinions Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2. Key question is whether in the light of the new data, the LDL-c goal will be maintained or lowered in high-CV risk individuals.
In ODYSSEY trials, LDL-lowering and adverse events were not different between patients with and without antidrug antibodies against PCSK9 antibody alirocumab.